p63 inhibits CD44+/CD24‑ cell proliferation and chemoresistance in papillary thyroid carcinoma cells

Guo,Jing‑Jing; Xu,Hong‑Shun; Wu,Gang; Ma,Zhen‑Yu

doi:10.3892/etm.2017.5137

p63 inhibits CD44+/CD24‑ cell proliferation and chemoresistance in papillary thyroid carcinoma cells

Authors:
- Jing‑Jing Guo
- Hong‑Shun Xu
- Gang Wu
- Zhen‑Yu Ma
View Affiliations

Affiliations: Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of General Surgery, Renhe Hospital, Shanghai 200043, P.R. China
Published online on: September 19, 2017 https://doi.org/10.3892/etm.2017.5137
Pages: 4693-4696
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer typically has a good prognosis; however, the risks of recurrence and chemoresistance associated with thyroid cancer remain a cause for concern. Papillary thyroid carcinoma (PTC) comprises 80% of all cases of thyroid carcinoma. A previous study reported that cluster of differentiation (CD) 44+/CD24‑ PTC cells may contribute to PTC recurrence and chemoresistance; however, the underlying molecular mechanisms remain elusive. In the present study, CD44+/CD24‑ cells were isolated from the TPC‑1 PTC cell line and biological function assays revealed that CD44+/CD24‑ cells were significantly more proliferative and chemoresistant compared with CD44‑/CD24‑ cells. Furthermore, the expression level of p63 was demonstrated to be negatively correlated with the expression of CD44 in PTC cells. The role of p63 in CD44+/CD24‑ cell proliferation and chemoresistance was investigated and, the ectopic expression of p63 was observed to significantly inhibit CD44+/CD24‑ cell proliferation and chemoresistance in vitro and in vivo. In conclusion, the present study indicated that CD44+/CD24‑ cells contribute to PTC proliferation and chemoresistance and that the suppression of p63 in CD44+/CD24‑ cells contributes to these effects.

View Figures

View References

1	Veiga LH, Neta G, Aschebrook-Kilfoy B, Ron E and Devesa SS: Thyroid cancer incidence patterns in Sao Paulo, Brazil, and the US SEER Program, 1997–2008. Thyroid. 23:748–757. 2013. View Article : Google Scholar : PubMed/NCBI
2	Vigneri R, Malandrino P and Vigneri P: The changing epidemiology of thyroid cancer: Why is incidence increasing? Curr Opin Oncol. 27:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sharma C: An analysis of trends of incidence and cytohistological correlation of papillary carcinoma of the thyroid gland with evaluation of discordant cases. J Cytol. 33:192–198. 2016. View Article : Google Scholar : PubMed/NCBI
4	Cobin RH, Gharib H, Bergman DA, Clark OH, Cooper DS, Daniels GH, Dickey RA, Duick DS, Garber JR, Hay ID, et al: AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocrine practice: Official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 7:202–220. 2001. View Article : Google Scholar : PubMed/NCBI
5	McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, et al: Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 24:35–42. 2014. View Article : Google Scholar : PubMed/NCBI
6	Heider KH, Kuthan H, Stehle G and Munzert G: CD44v6: A target for antibody-based cancer therapy. Cancer Immunol Immunother. 53:567–579. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ahn SH, Henderson YC, Williams MD, Lai SY and Clayman GL: Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab. 99:536–544. 2014. View Article : Google Scholar : PubMed/NCBI
8	Iida J, Clancy R, Dorchak J, Somiari RI, Somiari S, Cutler ML, Mural RJ and Shriver CD: DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration. PLoS One. 9:e887122014. View Article : Google Scholar : PubMed/NCBI
9	Yan W, Chen Y, Yao Y, Zhang H and Wang T: Increased invasion and tumorigenicity capacity of CD44+/CD24- breast cancer MCF7 cells in vitro and in nude mice. Cancer Cell Int. 13:622013. View Article : Google Scholar : PubMed/NCBI
10	Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, Shevde L and Rocconi RP: CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis. 29:939–948. 2012. View Article : Google Scholar : PubMed/NCBI
11	Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A and Cordon-Cardo C: p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 8:494–501. 2002.PubMed/NCBI
12	Deyoung M and Ellisen L: p63 and p73 in human cancer: Defining the network. Oncogene. 26:5169–5183. 2007. View Article : Google Scholar : PubMed/NCBI
13	Zhang J, Cho SJ and Chen X: RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc Natl Acad Sci USA. 107:9614–9619. 2010. View Article : Google Scholar : PubMed/NCBI
14	Miyauchi A, Kudo T, Hirokawa M, Ito Y, Kihara M, Higashiyama T, Yabuta T, Masuoka H, Shindo H, Kobayashi K and Miya A: Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J. 2:57–64. 2013. View Article : Google Scholar : PubMed/NCBI
15	Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J and Cheng C: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 121:1064–1074. 2011. View Article : Google Scholar : PubMed/NCBI
16	Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S and Nakshatri H: CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res. 8:R592006. View Article : Google Scholar : PubMed/NCBI
17	Chang G, Zhang H, Wang J, Zhang Y, Xu H, Wang C, Zhang H, Ma L, Li Q and Pang T: CD44 targets Wnt/beta-catenin pathway to mediate the proliferation of K562 cells. Cancer Cell Int. 13:1172013. View Article : Google Scholar : PubMed/NCBI